Brief: First Patient Dosed In Urogen Pharma’s Home Instillation Study Of UGN-102 In Patients With Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (Lg Ir-Nmibc)
21/12/2021 13:12
Dec 21 (Reuters) - Urogen Pharma Ltd UR8.F :
* FIRST PATIENT DOSED IN UROGEN PHARMA’S HOME INSTILLATION
STUDY
OF UGN-102 IN PATIENTS WITH LOW-GRADE INTERMEDIATE RISK
NON-MUSCLE INVASIVE BLADDER CANCER (LG IR-NMIBC)
Source text for Eikon: ID:nBw2p2sPya
Further company coverage: UR8.F
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors